Top 20 Companies in Global Antinuclear Antibody Test Market (2025–2035): Expert View by Spherical Insights
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The market for antinuclear antibody test includes of both technologies and testing products that help determine whether a patient has an autoimmune disease, such as systemic lupus erythematosus or rheumatoid arthritis. In November 2025, a global evaluation of the accessible medical literature indicates that about 50 % of tests for autoantibodies are done to help diagnose autoimmune disease, and 42% of the total number of tests for autoantibodies are done by hospitals, indicating a considerable institutional need for autoantibody testing.
In March 2025, India continues to develop laboratory infrastructure through two initiatives, such as the National Health Mission and Atmanirbhar Bharat. The government's priorities have changed to focus more on supporting the manufacture of auto-immunity testing products and technology by in-country suppliers via at least two programs: Make in India and Atmanirbhar Bharat. By establishing accessibility to laboratory-based immunodiagnostic testing services through Government (public) Hospital laboratories, the Government is trying to decrease its reliance on imported laboratory diagnostic tests and supplies. The market has significant opportunities due to increased prevalence of autoimmune diseases, expanding healthcare infrastructure, an increase in preventative healthcare, advances in technology, and government-assisted localization efforts.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Antinuclear Antibody Test Market.
Market Segmentation
Global Antinuclear Antibody Test Market Size, Share, By Product (Reagents & Assay Kits, Systems, Software & Services), By Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogrens Syndrome, Scleroderma, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035
Antinuclear Antibody Test Market & Statistics
- The Market Size for Antinuclear Antibody Test Was Estimated to be worth USD 1.73 Billion in 2024.
- The Market is Going to Expand at a CAGR of 13.67% between 2025 and 2035.
- The Global Antinuclear Antibody Test Market Size is anticipated to reach USD 7.08 Billion by 2035.
- North America is expected to generate the largest demand during the forecast period in the Antinuclear Antibody Test Market.
- Asia Pacific is expected to grow the fastest during the forecast period in the Global Antinuclear Antibody Test Market.
Regional Growth and Demand
Asia Pacific is expected to grow the fastest during the forecast period in the antinuclear antibody (ANA) test market. The region’s growth is driven by a large and aging population, a rising prevalence of autoimmune diseases, and increasing healthcare expenditure.
In April 2025, Sysmex Corporation’s new manufacturing facility in Gujarat, India, commenced full-scale operations. The facility produces diagnostic reagents and instruments, including the XQ-320 hematology analyzer, under India’s Make in India initiative, thereby strengthening domestic diagnostic manufacturing capabilities.
Asia Pacific also holds a significant share of the ANA test market due to improved healthcare infrastructure, growing awareness of early disease diagnosis, and increasing adoption of advanced diagnostic technologies.
North America is expected to generate the largest demand during the forecast period in the antinuclear antibody (ANA) test market. This growth is primarily driven by the high prevalence of autoimmune diseases, well-established healthcare infrastructure, and early adoption of advanced diagnostic technologies in the region.
Strategic collaborations between diagnostic companies and laboratories are further supporting market growth by enhancing automation, improving test accuracy, reducing turnaround times, and expanding testing capabilities.
Additionally, the ANA test market is projected to expand significantly due to the increasing burden of autoimmune disorders, along with technological advancements such as automation and AI-based interpretation, which improve diagnostic efficiency and throughput. Supportive healthcare policies and greater access to diagnostic services are also contributing to market growth.
Ready to lead the Antinuclear Antibody Test Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 trends in the Antinuclear Antibody Test Market
- Automation and AI integration in IIF testing
- Rising prevalence of autoimmune diseases
- Growth of multiplex assay technology
- Increasing use of reagent rental agreements
- Fastest growth in the Asia-Pacific region
- Adoption of specialized ANA profiling kits
- Standardization efforts
- Development of high-throughput reagents and assay kits
- Expansion of home testing and rapid tests
- Market consolidation through acquisitions
- Automation and AI integration in IIF testing
The industry is rapidly shifting from manual interpretation of Indirect Immunofluorescence (IIF) tests to automated systems and Artificial Intelligence (AI) for pattern recognition. Platforms like EUROPattern and ZEUS dIFine offer automated imaging, reducing human error, reducing turnaround time, and enhancing the consistency of pattern identification.
- Rising prevalence of autoimmune diseases
The rising incidence of autoimmune diseases like Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, and Sjogren’s syndrome is fueling global test volume. Approximately 8–10% of the global population suffers from some form of autoimmune disorder, driving consistent demand for diagnostic screening.
- Growth of multiplex assay technology
Multiplex assays are gaining popularity over traditional ELISA and IIF methods because they allow for the detection of multiple autoantibodies simultaneously from a single patient sample. This increases efficiency, lowers the cost per test, and provides comprehensive profiling.
- Increasing use of reagent rental agreements
To secure long-term contracts, many manufacturers are employing reagent rental agreements with laboratories. In this model, manufacturers provide automated, high-throughput analyzers free of charge or at low cost, provided the laboratory exclusively purchases their reagents, driving market stability.
- Fastest growth in the Asia-Pacific region
While North America currently dominates the ANA test market, the Asia-Pacific region is experiencing the fastest growth. This is driven by expanding healthcare infrastructure, rising disposable income, and increased awareness of autoantibody testing in countries like China, India, and Japan.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the antinuclear antibody test market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Antinuclear Antibody Test Market.
Top 10 Companies Leading the Antinuclear Antibody Test Market
- Abbott Laboratories
- Bio-Rad Laboratories, Inc
- Thermo Fisher Scientific, Inc
- F. Hoffmann-La Roche Ltd.
- Inova Diagnostics, Inc.
- ZEUS Scientific, Inc.
- Trinity Biotech plc
- Euroimmun Medizinische Labor Diagnostika AG
- PerkinElmer, Inc
- Grifols S.A.
- Abbott Laboratories
Headquarters: Abbott Park, Illinois, United States
Abbott Laboratories was founded in 1888 by Wallace Calvin Abbott and has developed into a global healthcare leader in diagnostics, medical devices, nutrition, and pharmaceuticals. The company offers a wide range of diagnostic solutions, including immunoassays and autoimmune testing, such as ANA tests. Abbott is known for its innovative diagnostic technologies that improve accuracy and efficiency in disease detection. The company operates manufacturing and research facilities worldwide and serves hospitals, laboratories, and healthcare providers. Abbott employs approximately 115,000+ people globally and generates an estimated annual revenue of USD 40-42 billion (2025). Its operations extend across North America, Europe, Asia-Pacific, and Latin America.
- Bio-Rad Laboratories, Inc.
Headquarters: Hercules, California, United States
Bio-Rad Laboratories, Inc. was founded in 1952 by David Schwartz and Alice Schwartz and has grown into a global leader in life science research and clinical diagnostics. The company provides a wide range of diagnostic products, including autoimmune disease testing systems such as ANA assays. Bio-Rad is known for its high-quality reagents and laboratory instruments that enhance diagnostic precision. The company operates globally, serving clinical laboratories, research institutions, and healthcare providers. Bio-Rad employs approximately 8,000+ people worldwide and generates an estimated annual revenue of USD 2.8-3.0 billion (2025). Its operations span North America, Europe, Asia-Pacific, and Latin America.
- Thermo Fisher Scientific Inc.
Headquarters: Waltham, Massachusetts, United States
Thermo Fisher Scientific, Inc. was founded in 2006 through the merger of Thermo Electron and Fisher Scientific and has become one of the world’s largest providers of scientific instruments, reagents, and diagnostic solutions. The company offers advanced immunoassay systems and autoimmune diagnostic tools, including ANA testing solutions. Thermo Fisher is known for its innovation in laboratory technologies and digital diagnostics. It operates globally, serving healthcare, research, and pharmaceutical industries. The company employs approximately 130,000+ people worldwide and generates an estimated annual revenue of USD 42-45 billion (2025). Its operations extend across North America, Europe, Asia-Pacific, and Latin America.
- F. Hoffmann-La Roche Ltd.
Headquarters: Basel, Switzerland
F. Hoffmann-La Roche Ltd. was founded in 1896 by Fritz Hoffmann-La Roche and is a global leader in pharmaceuticals and diagnostics. The company provides advanced diagnostic solutions, including immunodiagnostics and autoimmune disease testing such as ANA assays. Roche is known for its strong focus on innovation, precision medicine, and integrated healthcare solutions. It operates extensive research, manufacturing, and diagnostic facilities worldwide. Roche employs approximately 100,000+ people globally and generates an estimated annual revenue of USD 65-70 billion (2025). Its operations span Europe, North America, Asia-Pacific, and Latin America.
- Inova Diagnostics, Inc.
Headquarters: San Diego, California, United States
Inova Diagnostics, Inc. was founded in 1987 (part of Werfen) and has become a leading provider of autoimmune diagnostic solutions. The company specializes in the development of innovative immunoassay systems, including ANA testing kits used in clinical laboratories worldwide. Inova is known for its expertise in autoimmune disease diagnostics and high-quality testing platforms. The company operates globally, serving hospitals, laboratories, and research institutions. Inova Diagnostics employs approximately 1,000+ people worldwide and generates an estimated annual revenue of USD 200-300 million (2025). Its operations extend across North America, Europe, Asia-Pacific, and Latin America.
Are you ready to discover more about the antinuclear antibody test market?
The report provides an in-depth analysis of the leading companies operating in the global antinuclear antibody test market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global Antinuclear Antibody Test Market.
Company Profiles
- Abbott Laboratories
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Bio-Rad Laboratories, Inc
- Thermo Fisher Scientific, Inc
- F. Hoffmann-La Roche Ltd.
- Inova Diagnostics, Inc.
- ZEUS Scientific, Inc.
- Trinity Biotech plc
- Euroimmun Medizinische Labor Diagnostika AG
- PerkinElmer, Inc
- Grifols S.A.
- Immuno Concepts N.A. Ltd.
- Erba Diagnostics, Inc.
- Antibodies Incorporated
- QuidelOrtho Corporation
- ORGENTEC Diagnostika GmbH
- Becton, Dickinson and Company
- Merck KGaA
- AESKU.DIAGNOSTICS GmbH & Co. KG
- BioSystems S.A.
- Human Diagnostics Worldwide
Our Report
https://www.sphericalinsights.com/reports/italy-seed-treatment-market
https://www.sphericalinsights.com/reports/italy-compound-feed-market
https://www.sphericalinsights.com/reports/italy-data-center-market
https://www.sphericalinsights.com/reports/italy-food-colorants-market
Conclusion
Growth in the global Antinuclear Antibody (ANA) test market is continuing to accelerate sufficiently due to the developing trends relating to autoimmune diseases, population decline associated with age, and the associated increase in the need for early and accurate diagnostic testing. Continued development within the ANA Test Market will result from new technology advances in the areas of automation, machine learning, and multiplex testing, which will improve testing accuracy and volume, in addition to expanding laboratories supporting diagnostic testing and how diagnostic testing is found in up-and-coming geographical regions. North America remains the largest individual market to date. Still, Asia Pacific (APAC) will continue outpacing all other markets with strong overall growth through 2023. Key ANA test manufacturers, including Abbott Laboratories, Roche Diagnostics Corporation, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., and Inova Diagnostics, who are continually innovating in addition to expanding their global reach, developing capabilities that continue to advance diagnostics, whilst also helping create an environment for competitiveness across global healthcare systems.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?